{
  "units": [
    {
      "title": "Methods",
      "text": "Methods, including any statements of data availability and Nature Research\ncancer gene encoding a negative regulator of the WNT pathway34, reporting summaries, along with any additional references and Source Data files,\nrendered cells highly sensitive to the WNT secretion/porcupine are available in the online version of the paper at https://doi.org/10.1038/s41586-\n 018-0024-3.\ninhibitor IWP2 (Extended Data Fig. 10c). The remaining variation\nin drug response did not, however, clearly relate to the geographical Received: 26 January 2017; Accepted: 5 March 2018;\nzones of origin or to the phylogenetic trees of each cancer. There were Published online 11 April 2018.\nseveral examples of marked differences in drug sensitivity between\nclosely related clones. For example, P2.T4.1 showed marked resist- 1. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed\nance to SN-38 compared to the other P2.T4 clones, whereas P3.T1.5 by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).\n 2. de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability\nshowed distinct sensitivity to 5-FU compared to all other clones from processes defines lung cancer evolution. Science 346, 251–256 (2014).\nthis individual (Fig. 4 and Extended Data Fig. 10a). The mechanism 3. Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer.\nunderlying this diversification in biological behaviour is unclear, Nature 520, 353–357 (2015).\nbut there was no obvious correlation with the degree of mutational 4. Sottoriva, A. et al. A Big Bang model of human colorectal tumor growth.\n Nat. Genet. 47, 209–216 (2015).\ndiversification. 5. Uchi, R. et al. Integrated multiregional analysis proposing a new model of\n colorectal cancer evolution. PLoS Genet. 12, e1005778 (2016).\nDiscussion 6. Suzuki, Y. et al. Multiregion ultra-deep sequencing reveals early intermixing and\n variable levels of intratumoral heterogeneity in colorectal cancer. Mol. Oncol. 11,\nPrevious studies have addressed particular aspects of intra-cancer 124–139 (2017).\ndiversification by profiling the transcriptome, DNA copy number state 7. Navin, N. E. The first five years of single-cell cancer genomics and beyond.\nand functional responses of individual cells14–16,35. To our knowledge, Genome Res. 25, 1499–1507 (2015).\n 8. Gawad, C., Koh, W. & Quake, S. R. Single-cell genome sequencing: current state\nthis is the first systematic and integrated analysis at genetic, epigenetic, of the science. Nat. Rev. Genet. 17, 175–188 (2016).\ntranscriptomic and functional levels of multiple single-cell-derived 9. Leung, M. L. et al. Single-cell DNA sequencing reveals a late-dissemination\nclones from human cancers to incorporate high-quality and com- model in metastatic colorectal cancer. Genome Res. 27, 1287–1299 (2017).\n 10. Brocks, D. et al. Intratumor DNA methylation heterogeneity reflects clonal\nprehensive description of essentially all somatic mutations present in evolution in aggressive prostate cancer. Cell Reports 8, 798–806 (2014).\nmultiple single cells. All three cancers studied, including the two DNA 11. Oakes, C. C. et al. Evolution of DNA methylation is linked to genetic aberrations\nmismatch-repair proficient cases, clearly exhibited higher mutation in chronic lymphocytic leukemia. Cancer Discov. 4, 348–361 (2014).\n 12. Mazor, T. et al. DNA methylation and somatic mutations converge on the cell\nburdens than normal colorectal stem cells. These are likely to result cycle and define similar evolutionary histories in brain tumors. Cancer Cell 28,\nfrom increased mutation rates experienced during the lineages from 307–317 (2015).\nfertilized egg to colorectal cancer cell. More comparisons of normal 13. Caiado, F., Silva-Santos, B. & Norell, H. Intra-tumour heterogeneity — going\nand colorectal cancer cells, and similar comparisons for other classes of beyond genetics. FEBS J. 283, 2245–2258 (2016).\n 14. Stevens, M. M. et al. Drug sensitivity of single cancer cells is predicted by\ncancer, are required for corroboration but it seems likely that increases changes in mass accumulation rate. Nat. Biotechnol. 34, 1161–1167 (2016).\nin somatic mutation rates are common during the development of 15. Dubach, J. M. et al. Quantitating drug–target engagement in single cells in vitro\nhuman cancers. These increases are predominantly due to recruit- and in vivo. Nat. Chem. Biol. 13, 168–173 (2017).\n 16. Tirosh, I. et al. Single-cell RNA-seq supports a developmental hierarchy in\nment of mutational processes that are inactive or marginally active in human oligodendroglioma. Nature 539, 309–313 (2016).\nnormal cells, and which dominate at later stages in the evolution of 17. Macaulay, I. C. et al. G&T-seq: parallel sequencing of single-cell genomes and\nthe cancer cell population. The roles of these processes in generating transcriptomes. Nat. Methods 12, 519–522 (2015).\n 18. Li, H. et al. Reference component analysis of single-cell transcriptomes\ndriver mutations, however, are unclear, as they may have started before elucidates cellular heterogeneity in human colorectal tumors. Nat. Genet. 49,\nor after acquisition of the early driver mutations in the trunks of the 708–718 (2017).\ncancer phylogenetic trees5. The mechanisms underlying the increases 19. Angermueller, C. et al. Parallel single-cell sequencing links transcriptional and\n epigenetic heterogeneity. Nat. Methods 13, 229–232 (2016).\nin mutation rate in the DNA mismatch-repair proficient cancers are, 20. Meyer, M. et al. Single cell-derived clonal analysis of human glioblastoma\nfor the most part, unknown. These increases may be due to somatic links functional and genomic heterogeneity. Proc. Natl Acad. Sci. USA 112,\ngenetic or epigenetic changes (although these are not currently obvi- 851–856 (2015).\n 21. van de Wetering, M. et al. Prospective derivation of a living organoid biobank of\nous), to metabolic stress attendant upon the elevated mitotic rate and colorectal cancer patients. Cell 161, 933–945 (2015).\nother features of the neoplastic state, or to effects of the cancer cell 22. Sato, T. et al. Long-term expansion of epithelial organoids from human colon,\nmicroenvironment. Alongside intra-tumour mutational diversifi- adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141,\ncation, diversification of methylation state, transcriptome state and 1762–1772 (2011).\n 23. Behjati, S. et al. Genome sequencing of normal cells reveals developmental\nbiological responses to therapeutics occur. While some methylation lineages and mutational processes. Nature 513, 422–425 (2014).\nand transcriptome changes that occurred in vivo may have been lost 24. Blokzijl, F. et al. Tissue-specific mutation accumulation in human adult stem\nduring in vitro growth we were able to capture methylation and tran- cells during life. Nature 538, 260–264 (2016).\n 25. Cancer Genome Atlas Network. Comprehensive molecular characterization of\nscriptome changes that followed the evolution of the cancer through human colon and rectal cancer. Nature 487, 330–337 (2012).\nthe mutational phylogenetic tree, which appeared to be stable and, at 26. Tomlinson, I. P., Novelli, M. R. & Bodmer, W. F. The mutation rate and cancer.\nleast partly, independent of the tumour cell microenvironment, as they Proc. Natl Acad. Sci. USA 93, 14800–14803 (1996).\n 27. Loeb, L. A. Human cancers express a mutator phenotype: hypothesis, origin,\npersisted after cells were removed from the tumour. Diversification and consequences. Cancer Res. 76, 2057–2059 (2016).\nof methylation and transcriptome states and of drug responses are 28. Tomasetti, C. & Vogelstein, B. Variation in cancer risk among tissues can be\nlikely to result partly from driver mutations in cancer genes, but other, explained by the number of stem cell divisions. Science 347, 78–81 (2015).\n 29. Navin, N. E. Cancer genomics: one cell at a time. Genome Biol. 15, 452 (2014).\ncurrently unknown, genetic and/or epigenetic mechanisms may be 30. Sieber, O. M., Heinimann, K. & Tomlinson, I. P. M. Genomic instability—the\ninvolved36. Future studies analysing the genomes, methylomes and engine of tumorigenesis? Nat. Rev. Cancer 3, 701–708 (2003).\ntranscriptomes of primary cells of a cancer will be needed to reveal all 31. Snippert, H. J. et al. Intestinal crypt homeostasis results from neutral competition\n between symmetrically dividing Lgr5 stem cells. Cell 143, 134–144 (2010).\ngenetic, epigenetic and transcriptional variation occurring between 32. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer.\ncancer cells in vivo. Nevertheless, this study has shown the strength Nature 500, 415–421 (2013).\nof the organoid system in stably retaining these characteristics and 33. Alexandrov, L. B. et al. Clock-like mutational processes in human somatic cells.\nenabling functional assays on clones derived from individual cells. Nat. Genet. 47, 1402–1407 (2015).\n 34. Koo, B.-K. et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces\nThe analysis indicates that all three colorectal cancers contained cells endocytosis of Wnt receptors. Nature 488, 665–669 (2012).\nresistant to most of the drugs commonly used to treat the disease. 35. Dalerba, P. et al. Single-cell dissection of transcriptional heterogeneity in human\nDifferential drug responses between clones that are closely related both colon tumors. Nat. Biotechnol. 29, 1120–1127 (2011).\n 36. Landau, D. A. et al. Locally disordered methylation forms the basis of\ngenetically and epigenetically suggest that resistance mechanisms can intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell\narise late in tumorigenesis. 26, 813–825 (2014).\n\n 2 6 A P RIL 2 0 1 8 | V O L 5 5 6 | N A T U RE | 4 6 1\n © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.\n\nRESEARCH Article\n\nAcknowledgements We thank I. Martincorena, R. van Boxtel, J. Truszkowski, expression data. H.L., S.G. and P.J.C. contributed to statistical analyses. T.J.M.\nH. Francies and M. Garnett for discussion of our findings. This work was performed phylogeny analysis from the tissue biopsies. S.B. and M.v.d.W.\nsupported by funding from the Wellcome Trust (098051), Stichting Vrienden contributed to the study design. S.F.R. generated the figures. M.R.S. and H.C.\nvan het Hubrecht and KWF (SU2C-AACR-DT1213 and HUBR KWF 2014-6917). directed the study. M.R.S. wrote the manuscript with contributions from all\nIndividual authors were supported as follows: S.F.R., Louis-Jeantet Foundation; authors.\nN.S., JSPS Overseas Research Fellowships; H.L.-S., Wellcome Trust Nonclinical PhD Studentship; S.B., Wellcome Trust Intermediate Clinical Research Competing interests The authors declare no competing interests.\nFellowship and St. Baldrick’s Foundation Robert J. Arceci Innovation Award;\nP.J.C., Wellcome Trust Senior Research Fellowship in Clinical Science. Additional information\n Extended data is available for this paper at https://doi.org/10.1038/s41586-\nReviewer information Nature thanks M. Lawrence and the other anonymous 018-0024-3.\nreviewer(s) for their contribution to the peer review of this work. Supplementary information is available for this paper at https://doi.\n org/10.1038/s41586-018-0024-3.\nAuthor contributions A.P., N.Sm. and J.v.G. provided the samples and Reprints and permissions information is available at http://www.nature.com/\npathology information. N.Sa. generated organoid cultures and performed drug reprints.\nsensitivity assays. D.A.E. provided assistance with drug sensitivity assays. E.A., Correspondence and requests for materials should be addressed to M.R.S.\nS.J.G. and C.A. provided technical assistance. S.F.R. and H.L.-S. analysed and or H.C.\ninterpreted the sequencing data. H.L.-S. derived phylogenies. L.B.A. performed Publisher’s note: Springer Nature remains neutral with regard to jurisdictional\nsignature analysis. S.F.R. and M.D.Y. analysed and interpreted methylation and claims in published maps and institutional affiliations.\n\n\n4 6 2 | N A T U RE | V O L 5 5 6 | 2 6 A P RIL 2 0 1 8\n © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.\n\nArticle RESEARCH\n\nMethods developed cancer gene panel (CGPv3) was used, designed to pull down 360 genes\nHuman tissues. Tissue material was obtained from The Diakonessen Hospital, that are known or suspected to play a role in cancer3,37. The panel targets genes\nUtrecht. From the resected colon segment, both normal and tumour tissues were from the Cancer Gene Census (COSMIC), genes recurrently amplified or overisolated. The isolated tumour tissue was subdivided into 4–5 segments. Normal expressed in cancer and candidate cancer genes such as kinases from the MAP\ntissue was taken at least 5 cm away from the tumour. All samples were obtained kinase signalling pathway. We performed custom RNA bait design following the\nwith informed consent and the study was approved by the ethical committee of manufacturer’s guidelines (SureSelect, Agilent) and previously described work-\nThe Diakonessen Hospital, Utrecht. flows to create pulldown libraries from native genomic DNA3,37. Samples were\n No statistical methods were used to predetermine sample size. The experiments multiplexed on flow cells and subjected to paired end sequencing (75-bp reads)\nwere not randomized and the investigators were not blinded to allocation during using Illumina HiSeq2000 machines, resulting in more than 700× coverage for\nexperiments and outcome assessment. the target design for tumour-derived samples and more than 2,000× coverage for\nHuman organoid culture. Human normal and tumour colon organoids were normal tissue-derived samples. Sequences were aligned to the human reference\nestablished and maintained as described from isolated colonic epithelium21,22. genome (NCBI build37) using BWA-align.\nIn brief, long-term normal colonic organoid culture required human intestinal RNA sequencing. From each individual, RNA was isolated from all tumour\nstem cell medium (HISM) composed of advanced DMEM/F12 (AdMEM) with and normal derived organoid clones and subjected to RNA-seq analysis. RNApenicillin/streptomycin, 10 mM HEPES, 1×GlutaMAX, 1×B27 (Invitrogen) and seq libraries were prepared according to previously described workflows and\n1 µM N-acetylcysteine (SIGMA), supplemented with 50 ng ml−1 human recom- sequenced on Illumina HiSeq2000 machines38. Between four and seven barcoded\nbinant EGF (Peprotech), 0.5 µM A83-01 (Tocris), 3 µM SB202190 (SIGMA), 1 µM samples were pooled per library. Sequenced reads were aligned to the human refnicotinamide (SIGMA), 10 nM prostaglandin E2,Wnt3A-conditioned medium erence genome (NCBI build37) with Bowtie/TopHat.\n(CM) (50% final concentration), Noggin-CM (10% final concentration), and Methylation arrays. Infinium HumanMethylation450 BeadChip arrays were used\nR-Spondin1-CM (10% final concentration). Tumour organoids were cultured in to characterize the methylation status of more than 450,000 CpG sites for all clones.\nmedium containing only EGF, Noggin-CM, R-Spondin1-CM and A83-01. Mutation discovery. All somatic changes in whole genome and targeted data were\nEstablishment of clonal organoids. For clonal organoids from normal crypts, iso- analysed with mutation calling pipelines developed in house (available at https://\nlated single crypts were embedded in 10 µl Matrigel and cultured in HISM medium. github.com/cancerit).\nFor clonal tumour organoid cultures, tumour cell suspensions were cultured for Substitutions. Single-base somatic substitutions were identified using CaVEMan39\n7–14 days in HISM without Wnt3A-CM. Then, 10–15 individual organoids were and a number of post-processing filters were applied. For each patient, the only\npicked and separately dissociated into single cells by TryPLE express (Thermo germline reference available was healthy colorectal tissue more than 5 cm from the\nFisher), washed and suspended in AdMEM containing propidium iodide (PI). tumour, consisting of epithelial and connective tissue. In order to allow the discov-\nForty-eight single cells were sorted into tumour organoid medium (HISM plus 10 ery of a field effect40,41 that might have spread into the matched normal sample,\nμM ROCK inhibitor Y-27632 (Tocris BioScience); no Wnt-CM) from each tumour we ran CaVEMan using an unmatched normal reference. Germline SNPs were\norganoid. Sorting was based on FCS area/FCS peak and PIneg/FCS area using a removed by comparison to a panel of 75 unrelated normal samples. Additional\nMoflo machine (Beckman Coulter). Sorted cells were spun down at 1,000g at 4 °C post-processing filters were applied to these mutation calls as described42. For\nfor 5 min, after which single cells were each embedded into 10 µl of basement XTEN/BWA-mem aligned data we added two filters to the pipeline for the median\nmembrane extract (BME, Amsbio) and seeded into 96-well plates at a ratio of alignment score (ASMD) ≥ 140 and the clipping index (CLPM) = 0, meaning that\n1 cell per well. The gel was left to solidify in a 37 °C incubator after HISM (no fewer than half of the reads should be clipped.\nWnt3A-CM) was added. Y-27632 was added to the medium for the first week after We then tabulated the number of mutant and wild-type reads for every mutation\nsorting. For each original tumour organoid, a single clonal organoid was selected discovered in every sample, including the adjacent colorectal tissue. We considered\nand expanded for further study and for preparing frozen stocks. Culturing times only mutations that were covered by ten reads in all related clones, and mutations\nand plating efficiencies are listed for each organoid in Supplementary Datafile S1. that were seen on at least two reads in each direction. As the adjacent normal\nHistology procedures. Tissues were fixed in 4% formaldehyde solution overnight colorectal tissue is not entirely composed of epithelium we reasoned that if there\nand embedded in paraffin. Sections were subjected to haematoxylin and eosin were a field effect the somatic mutations in this tissue should not be fully clonal.\n(H&E) and immunohistochemistry staining. The Ki67 antibody (MONX10283, We therefore deducted germline mutations on the basis that they were fully clonal\nMonosan) was used at 1:250 dilution. in the bulk normal, while mutations that were subclonal in the bulk were not\nOrganoid CellTiter-Glo viability assay. Tumour organoids were cultured for 5–10 removed from the analysis. To define a mutation as subclonal in the bulk, the\ndays after being trypsinized into single cells in HISM without Wnt-3a-CM. The probability of finding the observed number of mutant reads or fewer given the\norganoids were mechanically dissociated by pipetting before being resuspended sequencing coverage had to be less than 0.005, based on the binomial distribution\nin 5% BME/growth medium (25 × 103 organoids per ml). Before seeding, 10 µl with a probability of 0.5 for autosomes. Mutations that failed to meet this criterion\nBME was dispensed into 384-well plates, and then 30 µl growth medium containing were considered to be germline and were removed.\norganoids was dispensed into each plate (at about 750 organoids per well. Drug Indels. Indels were called using Pindel43,44 using the adjacent bulk colorectal tissue\nscreening was carried out using nutlin-3a, afatinib, MEK1/2 inhibitor III, AKT as a matched normal. Post processing filters were the same as for substitutions\ninhibitor VIII, 5-FU, doxorubicin, and SN-38. Drug dilutions were performed in except that ASMD ≥ 140 and CLPM = 0 were not used.\ntwo series: 1) stepwise 2 fold-dilutions from 20 µM to 19.5 nM; and 2) stepwise 2 Copy number. Copy number profiles were constructed for WGS samples by\nfold-dilutions from 15 µM to 29.3 nM. The measurements for these two dilution ASCAT45,46, using adjacent healthy colorectal tissue as a matched normal. Copy\nseries were combined into a single curve. All drugs were dispensed by a HP-D300 number profiles of WGS analysed samples were visualized with the plotHeatmap\nautomated liquid dispenser (TECAN). Samples were incubated for 6 days at 37 °C, function of the R package ‘copynumber’47.\nand cell viability was measured by CellTiter-Glo 3D kit (Promega) on a SpectraMax Rearrangements. Rearrangements were called using healthy adjacent colorectal\nM5e (Molecular Devices). Cell viability measurements were performed in duplicate tissue as a matched normal. Abnormally paired read pairs from WGS were grouped\nwells for each clone. Survival ratios in drug-treated organoids were normalized and filtered by read remapping using ‘Brass’ (https://github.com/cancerit/BRASS).\nto the average survival in a DMSO control. Each experiment was repeated on a Read pair clusters with 50% or more of the reads mapping to microbial sequences\ndifferent day. To assess variability between technical and biological replicates we were removed. Candidate breakpoints were matched to copy number breakpoints\ncalculated the area under the curve (AUC) for each survival curve. AUC values defined by ASCAT within 10 kb. Rearrangements not associated with copy number\nare calculated using the trapezoid method and are divided by the area covered by breakpoints or with a copy number change of less than 0.3 were removed.\n100% survival on the y-axis and the range of the log10 concentrations on the x-axis Phylogenetic tree construction. The phylogeny of single-cell-derived organoids for\n(Extended Data Fig. 10b). each patient was constructed from substitutions called in WGS data. For each\nDNA and RNA extraction. DNA and RNA were concomitantly extracted from patient, substitutions that had been discovered by CaVEMan in any organoid from\nfrozen tissue samples or organoid cultures using AllPrep DNA/RNA minikit that patient were called as present or absent in each organoid using the algorithm\n(Qiagen 80204). Shearwater48. This algorithm compares allele frequencies of variants to a back-\nWhole-genome sequencing. From each individual, 7–10 tumour-derived clones ground error model derived from sequencing thousands of samples from unrelated\nwere selected for whole-genome sequencing (WGS), as well as 4–5 normal-derived studies on the same platform. Sequencing errors are known to occur at different\nclones. We generated paired end sequencing reads (150 bp) using Illumina XTEN frequencies across different sites of the genome48. By obtaining a comprehensive\nmachines, resulting in ± 30× coverage per sample. Sequences were aligned to the view of the number of variant calls at each position in unrelated normal genomes,\nhuman reference genome (NCBI build37) using BWA-MEM. Sequencing statistics we built an error model for each nucleotide change for each position. This method\nare listed in Supplementary Datafile S2. has previously been used to find variants at a low frequency49. Here, we com-\nCancer gene panel sequencing. All WGS sequenced clones and 40 additional pared the observed frequency of each variant to our error model. After correcting\ntumour-derived clones were subjected to targeted sequencing. An in-house for multiple testing, only variants that were significantly mutated over the error\n\n\n © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.\n\nRESEARCH Article\n\nmodel were kept, using a q value cutoff of 0.05. Although most true variants largely Second, we wanted to time substitutions in regions with a greater range of copy\nexceed this threshold, this procedure maximizes the chance of retaining variants in number states for mutational signature analysis. To do this, for every truncal subgenomic regions that have undergone copy number changes, lowering the appar- stitution in every tumour clone from patient 2, the copy number segment (as called\nent variant allele fraction (VAF), since the Shearwater algorithm was designed to by ASCAT) in which that mutation fell was defined. Mutations could be timed only\ndetect subclonal variants. As a further stringent filter to minimise false positive in samples in which there was a minor copy number of 0 and a major copy number\ncalls, variants had to be supported by at least three mutant reads to be considered greater than 1. Fortunately, because of the extensive copy number changes in this\nby the algorithm. In this way every mutation called in an individual was genotyped tumour, all mutations fell in a region that met these criteria in at least one sample.\nas being present or absent in each sample. Phylogenies were constructed using this For a given mutation that fell in such a copy number segment in a given sample, the\nbinary matrix of mutations present or absent in each sample. Private mutations VAF in that sample of known germline single nucleotide polymorphisms (SNPs)\nwere discarded from tree building as they are uninformative. A fake outgroup that fell in that segment (that necessarily occurred before the WGD) and the VAF\nwith no mutations called was generated for each individual. Phylogenies were of somatic mutations assigned to branches further down the tree (that necessarily\nconstructed using the Phylip suite of tools50. The programme seqboot was used occurred after the WGD) was examined. If, in a given sample, a mutation had a\nto generate 100 bootstrap replicates of each dataset by resampling the mutations VAF greater than 90% of the VAFs of the mutations that were known to occur\nwith replacement. Phylogenies were then reconstructed for each bootstrap replicate further down tree it was considered to have occurred before the WGD, whereas\nby maximum parsimony using the Mix programme using the Wagner method, if it had a VAF less than 90% of the VAFs of the SNPs it was considered to have\nusing the fake outgroup as a root. The jumble = 10 option was used, randomizing occurred after the WGD. If there was any overlap between the 90th percentiles of\nthe order of the input samples 10 times for each bootstrap replicate. Finally, the the SNPs and the later mutations, or if the mutation fitted neither of these criteria,\nprogramme Consense was used to build a consensus of all the trees that had been it was considered uninformative and was not used in the signature analysis. This\nbuilt for each patient, using the majority rule (extended) option. This reports, for accounted for 9,094 mutations (out of a total of 12,623 assigned to the trunk) that\neach node in the most parsimonious tree, how many of the trees that had been built were not used in signature analysis. There is no reason to believe that mutations\ncontain a node that partitions the samples into the same two groups. All nodes in that were excluded for these reasons should be attributable to different mutational\neach tree that relate tumour samples to each other were supported by all bootstrap signatures than those that could be included, and indeed their trinucleotide mutareplicates (Supplementary Notes). tion contexts are similar (data not shown). For each mutation, then, the number\nAssignment of somatic changes in WGS to the phylogenetic tree. Substitutions. of samples in which it had been counted before and after the WGD was tallied. If\nSubstitutions were called as present or absent in each organoid as described above. a mutation was called as occurring before the WGD in some samples and after the\nTo assign these mutations to the tree, each branch of the tree was considered in WGD in others, the mutation was designated as conflicting and excluded from\nturn. If a mutation was called in all the organoids that were descendants of a given the analysis. Eighty-two mutations fell into this category, and the remaining 3,447\nbranch, and in no organoids that were not descendants of the branch, muta- could be timed unambiguously relative to the WGD and used in the signature\ntions were assigned to that branch. Ignoring private mutations, which necessarily analysis. In Fig. 1 we extrapolated the preWGD and postWGD fractions and their\nfit any tree, 97.7% of shared mutations fitted the tree structure from patient 1 relative signature components to all mutations identified in the clonal trunk of P2.\nperfectly, 89.7% fitted the tree from patient 2 perfectly, and 88.1% fitted the tree Mutations that were included in the signature analysis, those that were excluded\nfrom patient 3 perfectly. The lower concordance with the tree for patients 2 and 3 as being uninformative, and those that were excluded as being conflicting, are\nreflects the increased copy number changes that have occurred in these phylog- reported in Supplementary Datafile S4.\nenies. Examination of the copy number state at loci where there were discordant Indels. For indels, we simply aimed to estimate the proportion that occurred before\nmutations showed that the majority could be explained by deletions of those and after the WGD, and so for this analysis we restricted ourselves to regions of the\nmutations in a subclone. Substitutions that did not fit the tree perfectly were genome with copy number 2 + 0. An analogous approach to timing substitutions\ntherefore assigned to the most recent common ancestor of the samples in which was taken, although rather than considering the distribution of germline indels\nthey were called. and indels further down the tree, a hard VAF cutoff of 0.85 (which separated the\n All substitution calls and their assignment to branches of the tree, as well as bimodal distribution of indel VAFs in these loci) was used to define mutations as\nsubstitutions that did not fit the tree perfectly and their associated copy number occurring before or after the WGD.\nstates are listed in Supplementary Data file S4. Rearrangements. We timed rearrangements relative to the WGD in patient 2 by\nIndels. Indels were called as being present or absent in each sample based on a using the copy number step associated with deletions and tandem duplications\nvariant allele fraction (the proportion of mutant reads at a locus) cutoff. The in the trunk of this tumour, as determined by inspection of the change in read\nvariant allele fraction cutoff was chosen for each patient based on a histogram of counts at breakpoints. The ratio of tandem duplications and deletions that had\nthe variant allele fraction to separate the sequencing noise distribution from the occurred before rather than after the WGD was extrapolated to give a ratio for all\ndistribution of true mutations. Variant allele fraction cutoffs were chosen as 0.15 the rearrangements in the trunk, assuming that the relative proportion of different\nfor patients 1 and 3, and 0.11 for patient 2. Indels were then assigned to branches rearrangement classes stayed the same after the WGD.\nof the tree that they fitted perfectly. Indels that were assigned to the tree, along Driver mutations. Driver mutations in TP53 and APC were timed relative to the\nwith their assignments, as well as indels that did not fit the tree are provided in WGD in patient 2. The TP53 mutation was at VAF 1 in a region that was 2 + 0 in\nSupplementary Data file S4. all samples, indicating that it occurred before the WGD. There were mutations in\nRearrangements. The same rearrangement may be called in related samples with both alleles (which we will call mutation 1 and mutation 2) of APC. P2.T4.2 and\nslightly different breakpoints. To identify rearrangements that had been sequenced P2.T5.1 both had the APC locus called as 2 + 2, and both mutations were at VAF\nin related clones as the same, both the upstream and the downstream breakpoints 0.5. P2.T1.1, P2.T1.3, and P2.T6.2 were 2 + 1 in the APC region. Mutation 1 was\nhad to fall within 500 bp of each other. The majority of rearrangements fitted the at VAF 0.67 and mutation 2 at 0.33. In P2.T2.5 the region was also called as 2 + 1,\ntree. Visualization of discordant rearrangements using IGV51 showed that often an but mutation 1 was at VAF 0.33 and mutation 2 at VAF 0.67. This shows biallelic\noverlapping rearrangement meant that the rearrangement was lost in a clone. All inactivation of APC before the WGD.\nrearrangement calls that could and could not be assigned to the tree can be found Assignment of samples to the tree based on targeted sequencing. Samples for which\nin Supplementary Data file S4. both WGS and targeted sequencing were available were used to estimate the sen-\nTiming substitutions and indels relative to a whole genome duplication (WGD). A sitivity in the targeted data for finding substitutions that were identified in each\nwhole genome duplication was observed in the trunk of the tumour for patient 2. branch by the WGS data. The targeted capture was designed against 360 cancer\nSubstitutions. For substitutions, we aimed first to obtain an accurate estimate genes; in addition, all off-target reads that covered substitutions identified by WGS\nof the timing of WGD in molecular time, and second to time as many substi- were considered. For example, in clone P1.T1.1, a fraction of 0.09 of all substitututions as possible relative to the WGD in order to perform signature analysis tions in the ultimate branch P1.T1.1 was found in the targeted data. Samples for\non them. which only targeted sequencing was available were then assigned to the ultimate\n To obtain an estimate of the timing of the WGD, we examined substitutions branch of the tree with which they shared most substitutions. For example, clone\nin regions with two copies of one allele and none of the other (as determined by P1.T1.4 shared a fraction of 0.04 with branch P1.T1.1 and negligible fractions\nASCAT). In these regions, if a mutation occurred before the WGD on that allele, with other branches. To estimate the time point at which P1.T1.4 branched off, we\nit will be at copy number 2. If it occurred afterwards, it will be at copy number 1. divided the shared fraction 0.04 in clone P1.T1.4 by the sensitivity in clone P1.T1.1\nOne hundred and eighty substitutions occurred at copy number 2, and 67 at copy 0.09. Thus, we estimated that P1.T1.4 shares 0.04/0.09 = 43% of mutations with\nnumber 1. As at least half of the mutations that occurred before the WGD have branch P1.T1.1. The proportion of mutations shared with each branch are listed\nbeen lost in such regions (as there is loss of one allele), the WGD can be estimated in Supplementary Notes section 2.\nto have occurred at 84% ((180 × 2)/(180 × 2 + 67)) of molecular time in the trunk Driver analysis. To classify driver events in substitutions, indels and rearrangeof the tumour (95% confidence interval of 80.8–87.6% calculated by bootstrapping ments we used the following criteria: 1) deleterious mutations in genes iden-\n10,000 times). tified in CRC by TCGA25; 2) all other known oncogenes carrying a canonical\n\n\n © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.\n\nArticle RESEARCH\n\nactivating mutation; and 3) tumour suppressor genes with loss of function, and/ Custom R scripts developed for the analyses and visualizations in this manuor carrying two deleterious mutations. A more inclusive approach for identify- script are available from the authors on request.\ning functional mutations is listed in Supplementary Datafile S3 and described in Data access. Sequencing data have been deposited at the European Genomethe Supplementary Notes. Phenome Archive (http://www.ebi.ac.uk/ega/) under accession numbers\nMutational signature analysis. Signature extraction based on non-negative matrix EGAS00001000869 (targeted sequencing), EGAS00001000985 (RNA-seq) and\nfactorization was performed as previously described32,52. Mutations in trinucleotide EGAS00001000881 (WGS). RNA sequencing data of these organoid clones has\ncontext were grouped according to branches of the phylogenetic tree or according also been described elsewhere60.\nto sample. Datasets were combined with data from 560 breast cancer genomes to\nincrease performance of the NNMF procedure53. 37. Yates, L. R. et al. Subclonal diversification of primary breast cancer revealed by\nExpression analysis. Clustering analyses were based on FPKM values calculated multiregion sequencing. Nat. Med. 21, 751–759 (2015).\n 38. Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166,\nwith the Cufflinks algorithm54. To select informative genes for clustering we applied 740–754 (2016).\nthe following filters: FPKM > 1; coefficient of variation across all samples > 0.7 or 39. Jones, D. et al. cgpCaVEManWrapper: Simple execution of CaVEMan in order to\nabsolute difference > 5. Subsequently, FPKM values were log2 transformed and detect somatic single nucleotide variants in NGS data. Curr. Protoc.\nnormalized. Normalization across samples was applied by subtracting the median Bioinformatics 56, 15.10.1–15.10.18 (2016).\nexpression value from individual expression values. Normalization across genes 40. Lochhead, P. et al. Etiologic field effect: reappraisal of the field effect concept in\n cancer predisposition and progression. Mod. Pathol. 28, 14–29 (2015).\nwas applied by subtracting the gene’s median expression from individual expression\n 41. Luo, Y., Yu, M. & Grady, W. M. Field cancerization in the colon: a role for aberrant\nvalues. Normalized values were subjected to principle component analysis (PCA). DNA methylation? Gastroenterol. Rep. (Oxf.) 2, 16–20 (2014).\n For each tumour clone we calculated a set of genes differentially expressed 42. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast\ncompared to all normal clones pooled together. Genes were called as differen- cancers. Cell 149, 979–993 (2012).\ntially expressed if they had an FDR-corrected P value less than 0.05, resulting 43. Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth\nfrom a likelihood ratio test using a negative binomial generalized linear model approach to detect break points of large deletions and medium sized insertions\n from paired-end short reads. Bioinformatics 25, 2865–2871 (2009).\nfit with the R package ‘edgeR’55. Raw counts were input into the edgeR model, 44. Raine, K. M. et al. cgpPindel: identifying somatically acquired insertion and\nalong with normalization offsets calculated using the TMM method56. To construct deletion events from paired end sequencing. Curr. Protoc. Bioinformatics 52,\nthe expression-based phylogenetic trees, we calculated Euclidean distances based 15.7.1–15.7.12 (2015).\non all genes that were differentially expressed in at least one tumour clone from 45. Raine, K. M. et al. ascatNgs: identifying somatically acquired copy-number\nthat individual. Trees were inferred by the minimum evolution method, with the alterations from whole-genome sequencing data. Curr. Protoc. Bioinformatics 56,\n 15.9.1–15.9.17 (2016).\nfast-me.bal function in the R-package ‘ape’57. 46. Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad.\nMethylation analysis. Methylation arrays were processed using the R package Sci. USA 107, 16910–16915 (2010).\nminfi58. We excluded three samples that failed standard QC metrics (more than 47. Nilsen, G. et al. Copynumber: Efficient algorithms for single- and multi-track\n1,000 failed probes). We then excluded any probe from the analysis if it contained copy number segmentation. BMC Genomics 13, 591 (2012).\na variant identified in one of the samples, had a detection P value > 1 × 10−10 48. Gerstung, M., Papaemmanuil, E. & Campbell, P. J. Subclonal variant calling\n with multiple samples and prior knowledge. Bioinformatics 30, 1198–1204\nin > 10% samples or one sample with P > 0.01, occurred at a location known to\n (2014).\ncross-hybridize with another genomic location, or where there was a known SNP 49. Martincorena, I. et al. Tumor evolution. High burden and pervasive positive\nat the CpG targeted by the probe. The remaining probes were then normalized selection of somatic mutations in normal human skin. Science 348, 880–886\neither using the ‘preprocessRaw’ function when comparing all samples together or (2015).\nusing the SWAN quantile-normalization method when comparing clones from a 50. Felsenstein, J. PHYLIP — Phylogeny Inference Package (Version 3.2). Cladistics\nparticular tumour59. The latter method is appropriate when the number of meth- 5, 164–166 (1989).\n 51. Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24–26 (2011).\nylated probes is expected to be roughly constant across all samples, which was 52. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R.\nthe case for each tumour. For all comparisons, M values (log2 ratio of methylated Deciphering signatures of mutational processes operative in human cancer.\nto unmethylated probes) were calculated from the normalized probe intensities. Cell Reports 3, 246–259 (2013).\nSamples were clustered using PCA. For computational reasons, we used only the 53. Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer\n1,000 most variable probes for PCA. whole-genome sequences. Nature 534, 47–54 (2016).\n 54. Trapnell, C. et al. Differential gene and transcript expression analysis of\n Probes that were differentially methylated between tumour and normal cells RNA-seq experiments with TopHat and Cufflinks. Nat. Protocols 7, 562–578\nwere identified using an F-test with variance shrinking and a false discovery rate (2012).\nof 0.01 via the ‘dmpFinder’ function comparing each tumour clone to all normal 55. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package\nderived clones58. To construct the methylation-based phylogenetic trees, we cal- for differential expression analysis of digital gene expression data.\nculated Euclidean distances based on probes that were differentially methylated Bioinformatics 26, 139–140 (2010).\n 56. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential\nin at least one tumour clone from that individual. For computational reasons, we\n expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).\nused a q-value cutoff of 1 × 10−8 for selection of informative probes. Trees were 57. Desper, R. & Gascuel, O. Fast and accurate phylogeny reconstruction\ninferred by the minimum evolution method, with the fast-me.bal function in the algorithms based on the minimum-evolution principle. J. Comput. Biol. 9,\nR-package ‘ape’57. 687–705 (2002).\nReporting summary. Further information on experimental design is available in 58. Aryee, M. J. et al. Minfi: a flexible and comprehensive Bioconductor package for\nthe Nature Research Reporting Summary linked to this paper. the analysis of Infinium DNA methylation microarrays. Bioinformatics 30,\n 1363–1369 (2014).\nCode availability. Mutation calling pipelines developed in house are available at 59. Maksimovic, J., Gordon, L. & Oshlack, A. SWAN: Subset-quantile within array\nhttps://github.com/cancerit. The Shearwater algorithm for deriving a background normalization for illumina infinium HumanMethylation450 BeadChips.\nerror model is available at: https://www.bioconductor.org/packages/devel/bioc/ Genome Biol. 13, R44 (2012).\nvignettes/deepSNV/inst/doc/shearwaterML.html. The software for signature 60. Borten, M. A., Bajikar, S. S., Sasaki, N., Clevers, H. & Janes, K. A. Automated\nanalysis used in this manuscript is available at: https://www.mathworks.com/ brightfield morphometry of 3D organoid populations by OrganoSeg. Sci. Rep.\n (in the press).\nmatlabcentral/fileexchange/38724-wtsi-mutational-signature-framework.\n\n\n © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.\n\nRESEARCH Article\n\n\nExtended Data Fig. 1 | Origin of clonal organoids analysed in this study. tumour, 4–6 segments were resected (sized 5 × 5 × 3–5 mm. All sections\nSpecimens were derived from the ascending colon of a 66-year-old woman except T3 from P2 resulted in viable clonal organoids. b–f, h–n, p–t,\n(a–f), sigmoid rectum of a 65-year-old woman (g–n) and ascending Haematoxylin and eosin staining and Ki67 immunohistochemistry show\ntransverse colon of a 56-year-old man (o–t), respectively. From each cell morphology for individual tumour sections. Scale bars: 200 µm.\n\n\n © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.\n\nArticle RESEARCH\n\n\nExtended Data Fig. 2 | Substitution analysis. a, Comparison of phylogeny signature identified in this study in tumour organoid samples from P3,\nreconstructions from WGS analysis of clonal organoids (left) and characterized by T > G, T > A and T > C mutations at NTA and NTT\nsubclonal analysis of the original tissue biopsies (right) from individuals trinucleotides (mutated bases underlined). e, Contribution of each of the\nP1–P3. The analysis of clonal organoids allows a very detailed phylogeny, identified mutation signatures to individual samples. Top (by_sample),\nexact placement of driver mutations and analysis of cell-to-cell differences. results of signature extraction from all substitutions identified in each\nb, Venn diagrams depicting overlap between substitutions identified by sample (Supplementary Notes). Bottom, proportion in each sample\nthe organoid approach and the tissue biopsy approach. c, Venn diagrams derived by adding up proportions in the branches of the phylogenetic\ndepicting overlaps between clones P2.N3 and P2.T6.2 and their respective tree that make up that sample (identical to Fig. 1). f, Numbers of C > T\nsubclones (see Methods). Only a small proportion of the total mutations mutations by CpG context. g, Signature analysis of substitutions identified\nis added during culturing in both normal and tumour organoids. d, New in the original tissue biopsies.\n\n\n © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.\n\nRESEARCH Article\n\n\nExtended Data Fig. 3 | Phylogenetic trees for clones that have numbers; labels of nodes and tips in the tree correspond with labels in\nbeen analysed by WGS. Branch lengths represent total mutation Supplementary Data files S3–S5.\n\n\n © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.\n\nArticle RESEARCH\n\n\nExtended Data Fig. 4 | Phylogenetic trees for indels. Phylogenies for number of indels in this patient, who displays microsatellite instability\nthree individuals with branch lengths representing indel numbers, further (MSI) in all tumour clones in a different scale.\nsubdivided in insertions and deletions. Boxed area for P1 shows the high\n\n\n © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.\n\nRESEARCH Article\n\n\nExtended Data Fig. 5 | Phylogenetic trees for rearrangements. rearrangement numbers, further subdivided into deletions, inversions,\nPhylogenies for three individuals with branch lengths representing tandem duplications and translocations.\n\n\n © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.\n\nArticle RESEARCH\n\n\nExtended Data Fig. 6 | Copy number analysis. Copy number profiles (amplification in red, loss in blue). The structures of the phylogenetic trees\nof all clones that have been WGS analysed, displayed as a heatmap are displayed on the left; branch lengths are not scaled.\n\n\n © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.\n\nRESEARCH Article\n\n\nExtended Data Fig. 7 | MLH1 hypermethylation in P1. a–c, Methylation start site (TSS) for P1 tumour clones compared to normal clones.\npattern of the MLH1 gene for tumour and normal clones for three d, Expression of MLH1 in all clones; MLH1 transcript could not be\nindividuals, showing hypermethylation in proximity to the transcription detected in tumour clones from P1.\n\n\n © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.\n\nArticle RESEARCH\n\n\nExtended Data Fig. 8 | Methylation analysis. a, Clustering of methylation based on expression data (as in Fig. 3b) with the main branches used for\ndata by PCA showing normal-derived organoids from three individuals our methylation analysis indicated. c, P1, n = 20 biologically independent\n(n = 12 biologically independent samples). b, Global methylation change samples. d, P2, n = 21 biologically independent samples. e, P3, n = 17\nin each tumour clone, expressed as the ratio of hypermethylated probes biologically independent samples. f–h, Direction of methylation changes\nto hypomethylated probes. Hyper- and hypomethylation are assessed during tumour development. Methylation changes were assigned to either\nby comparing to the baseline methylation levels in the normal-derived the branch of the tumour or the main subclonal branches (indicated in the\nclones (indicated with line at y = 1). c–e, Left, clustering of methylation phylogenetic trees in e). i–k, Relative proportion of probes in CpG islands,\ndata by PCA of tumour organoids from each individual, displaying the shores, shelves and seas that were differentially methylated in different\nfirst two principal components. Clones from different segments are shown branches (Supplementary Notes section 6).\nin different colours as in Extended Data Fig. 2. Right, phylogenetic trees\n\n\n © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.\n\nRESEARCH Article\n\n\nExtended Data Fig. 9 | Expression analysis. a, PCA based on expression samples. e–g, Global analysis of expression changes attributed to the trunk\npattern of normal organoids from each individual, displaying the first of the tree, the main branches or subclonal variation. h, Venn diagram\ntwo principal components (n = 13). A subclone and its ancestral clone displaying the differentially expressed genes that were attributed to the\nare circled. b–d, Left, PCA of tumour clones from each individual. trunk of each tumour. Differentially expressed genes determined by a\nClones derived from different segments are shown in different colours likelihood ratio test using a negative binomial generalized linear model fit\nas in Figs. 2–4. A subclone derived from a tumour clone from P2 and its (FDR < 0.05). i–k, Comparison of differentially expressed genes identified\nancestor clone are circled. Right, phylogenetic trees based on expression in the organoid clones of each patient versus the original tissue sections.\ndata (as in Fig. 4b) with the main branches used for our expression analysis Only genes that were significantly altered in all clones or all biopsies from\nindicated. b, P1, n = 20 biologically independent samples. c, P2, n = 22 each individual are considered.\nbiologically independent samples. d, P3, n = 17 biologically independent\n\n\n © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.\n\nArticle RESEARCH\n\n\nExtended Data Fig. 10 | Drug response data. Dose response data for in duplicate (biological replicate). For each biological or technical replicate\nseven drugs, tested on organoid clones from three individuals. Twenty-one the area under the curve (AUC) is shown. c, Dose–response curves after\nconcentrations were tested for each drug, ranging from 14.7 nm to 20 μM. 6 days of treatment with IWP2 (Wnt secretion inhibitor) for clonal tumour\nMean survival from two duplicate experiments is displayed in a heatmap. organoids derived from P1. RNF43 mutant clones are responsive, whereas\nThe concentration displayed in Fig. 4 is outlined with a black box in each RNF43 wild-type (WT) clones are resistant. Data points and error bars\npanel. b, Reproducibility of drug response data. Each measurement was represent the mean and s.d. of four independent technical replicates from\nperformed twice (technical replicate) and each experiment was performed two independent experiments.\n\n\n © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.\n\nnature research | life sciences reporting summary\n Michael R Stratton(mrs@sanger.ac.uk);\n Corresponding author(s): Hans Clevers (h.clevers@hubrecht.eu)\n Initial submission Revised version Final submission\n\nLife Sciences Reporting Summary\nNature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life\nscience papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list\nitems might not apply to an individual manuscript, but all fields must be completed for clarity.\nFor further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research\npolicies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.\n\n\n` Experimental design\n1. Sample size\n Describe how sample size was determined. No statistical methods were used to predetermine sample size.\n\n2. Data exclusions\n Describe any data exclusions. We excluded one normal derived clone from P1 from our analysis. Although all\n characteristics (mutation numbers and signatures) were in the range of the other\n normals, we could not confirm that this clone was an independent sample or a\n subsample from P1.N.2. None of our conclusions would be affected by either\n including or excluding this sample.\n3. Replication\n Describe whether the experimental findings were Drug response testing has been replicated and reliably reproduced (extended data\n reliably reproduced. figure 10)\n4. Randomization\n Describe how samples/organisms/participants were Not relevant to this study; we describe each case on itself and do not make\n allocated into experimental groups. assumptions on groups that they represent.\n5. Blinding\n Describe whether the investigators were blinded to Investigators were blinded to each cloneID, but not individual's ID during data\n group allocation during data collection and/or analysis. collection and analysis. The reason for this is that samples from the three\n individuals were collected at different timepoints - ie after they underwent surgery.\n Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.\n\n6. Statistical parameters\n For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the\n Methods section if additional space is needed).\n\nn/a Confirmed\n\n The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)\n A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same\n sample was measured repeatedly\n A statement indicating how many times each experiment was replicated\n The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more\n complex techniques should be described in the Methods section)\n A description of any assumptions or corrections, such as an adjustment for multiple comparisons\n June 2017\n\n\n The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted\n A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)\n Clearly defined error bars\n\n See the web collection on statistics for biologists for further resources and guidance.\n\n\n 1\n\n` Software\n\n\n nature research | life sciences reporting summary\nPolicy information about availability of computer code\n7. Software\n Describe the software used to analyze the data in this alignment:\n study. BWA-aln version 0.5.9-r16+rugo (targeted data)\n BWA-mem version 0.7.12-r1039 (whole genome data)\n variant calling:\n Caveman 1.11.0 (available from https://github.com/cancerit)\n Pindel 2.1.0 (available from https://github.com/cancerit)\n Brass 3.0.4 (available from https://github.com/cancerit)\n ASCAT 1.5.1 (available from https://github.com/cancerit)\n copynumber 1.16.0 (R package available from https://bioconductor.org/packages/\n release/bioc/html/copynumber.html)\n ShearwaterML: R package deepSNV version 1.21.4 available from https://\n www.bioconductor.org/packages/devel/bioc/vignettes/deepSNV\n Phylogeny analysis:\n phylip suite of tools: phylip-3.695 (available from http://\n evolution.genetics.washington.edu/phylip.html)\n ape 4.1 (R package available from https://cran.r-project.org/web/packages/ape/\n index.html)\n Signature extraction: available from https://www.mathworks.com/matlabcentral/\n fileexchange/38724-wtsi-mutational-signature-framework\n RNAseq analysis:\n Bowtie 0.12.7\n TopHat 1.3.3\n Cufflinks 1.0.2\n GoSeq 1.30.0 (Rpackage available from https://bioconductor.org/packages/\n release/bioc/html/goseq.html)\n edgeR 3.20.2 (R package available from http://bioconductor.org/packages/release/\n bioc/html/edgeR.html)\n Methylation analysis:\n minfi 1.24.0 (R package available from https://bioconductor.org/packages/release/\n bioc/html/minfi.html)\n\n Custom Rscripts to create the figures of this manuscript have been developed in\n R-3.1 for this manuscript and are available upon request from the authors).\n For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made\n available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for\n providing algorithms and software for publication provides further information on this topic.\n\n` Materials and reagents\nPolicy information about availability of materials\n8. Materials availability\n Indicate whether there are restrictions on availability of All unique materials are available from the authors upon request.\n unique materials or if these materials are only available\n for distribution by a for-profit company.\n9. Antibodies\n Describe the antibodies used and how they were validated Ki67 antibody (MONX10283, Monosan) was used and extensively validated for use\n for use in the system under study (i.e. assay and species). in human colorectal tissue in previous work (eg Drost et al, Nature 2015)\n\n10. Eukaryotic cell lines\n a. State the source of each eukaryotic cell line used. No eukaryotic cell lines were used.\n\n b. Describe the method of cell line authentication used. No eukaryotic cell lines were used\n June 2017\n\n\n c. Report whether the cell lines were tested for no eukaryotic cell lines were used\n mycoplasma contamination.\n\n d. If any of the cell lines used are listed in the database no commonly misidentified cell lines were used\n of commonly misidentified cell lines maintained by\n ICLAC, provide a scientific rationale for their use.\n\n\n 2\n\n` Animals and human research participants\n\n\n nature research | life sciences reporting summary\nPolicy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines\n11. Description of research animals\n Provide details on animals and/or animal-derived No animals were used\n materials used in the study.\n\nPolicy information about studies involving human research participants\n12. Description of human research participants\n Describe the covariate-relevant population Samples from 3 individuals have been studied:\n characteristics of the human research participants. P1 is a 66 yo male with a tumour in the ascending colon\n P2 is a 65 yo male with a tumour in the sigmoid rectum\n P3 is a 56 yo female with a tumour in the ascending - transverse colon\n\n\n June 2017\n\n\n 3",
      "rationale": "heuristic fallback",
      "detected_categories": [
        {
          "id": "molecular_cloning",
          "hits": 84,
          "confidence": 1.0,
          "matched_patterns": [
            "clon",
            "insert",
            "transform"
          ]
        },
        {
          "id": "dna_rna_extraction",
          "hits": 48,
          "confidence": 1.0,
          "matched_patterns": [
            "rna extraction",
            "lysis"
          ]
        },
        {
          "id": "sequencing_library_prep",
          "hits": 48,
          "confidence": 1.0,
          "matched_patterns": [
            "sequenc",
            "illumina",
            "hiseq",
            "paired end",
            "library"
          ]
        },
        {
          "id": "cell_culture",
          "hits": 13,
          "confidence": 1.0,
          "matched_patterns": [
            "cultured",
            "incubat",
            "\\bwell\\b"
          ]
        },
        {
          "id": "animal_experiment",
          "hits": 3,
          "confidence": 0.6,
          "matched_patterns": [
            "in vivo"
          ]
        }
      ],
      "split_audit": {
        "char_count": 59340,
        "word_count": 9370,
        "sentence_count": 934,
        "category_count": 5,
        "flags": [
          "UNIT_CATEGORY_OVERMIXED"
        ]
      }
    }
  ],
  "created_at": "2026-02-16T10:57:25.985231+00:00"
}